1-3 of 3
Catherine Jia, PhD
Close
Sort by
Journal Articles

Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).

Mikkael A. Sekeres, MD, MS, Aristoteles Giagounidis, MD, Hagop M. Kantarjian, MD, Ghulam J. Mufti, MD, Pierre Fenaux, Catherine Jia, PhD, Allen S. Yang, MD, PhD, Uwe Platzbecker, MD
Journal: Blood
Blood (2012) 120 (21): 2801.
https://doi.org/10.1182/blood.V120.21.2801.2801
Published: 2012
Journal Articles

Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)

Pierre Fenaux, MD, PhD, Hagop M. Kantarjian, Petra Muus, MD, PhD, Roger M. Lyons, MD, Richard A. Larson, MD, Mikkael A. Sekeres, MD, MS, Pamela S. Becker, MD, PhD, Catherine Jia, PhD, Allen S. Yang, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2772.
https://doi.org/10.1182/blood.V118.21.2772.2772
Published: 2011
Journal Articles

Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)

Pierre Fenaux, MD, PhD, Hagop Kantarjian, MD, Roger M Lyons, MD, Richard A Larson, MD, Mikkael A Sekeres, MD, MS, Pamela Becker, MD, PhD, Petra Muus, MD, PhD, Catherine Jia, PhD, Allen S Yang, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1885.
https://doi.org/10.1182/blood.V116.21.1885.1885
Published: 2010